MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema
Status:
Recruiting
Trial end date:
2022-10-18
Target enrollment:
Participant gender:
Summary
This is an open label dose-escalation study to evaluate the safety and treatment benefits of
MS-553 in treatment-naive diabetic retinopathy patients with central involved macular edema.
Fifteen subjects with diabetic macular edema will be enrolled into each of three dose cohorts
and will receive oral administration of MS-553 for 8 weeks.